Grifols: new biological manufacturing facility in California
(CercleFinance.com) - Spanish healthcare company Grifols said it has recently received approval from the US Food & Drug Administration to relocate existing immuno-diagnostic operations to a new 80 million dollar, state-of-the-art, biological manufacturing facility in the San Francisco Bay Area.
This first submission enables commercial manufacturing practices, such as fermentation, purification, and bulk fill operations in the facility, the company said.
Additional submissions to the FDA are planned to relocate the production of other licensed recombinant protein products.
Once the transition is complete in mid-2019, pending FDA approvals, Grifols will transfer 21 products to the Emeryville, California-based manufacturing facility.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This first submission enables commercial manufacturing practices, such as fermentation, purification, and bulk fill operations in the facility, the company said.
Additional submissions to the FDA are planned to relocate the production of other licensed recombinant protein products.
Once the transition is complete in mid-2019, pending FDA approvals, Grifols will transfer 21 products to the Emeryville, California-based manufacturing facility.
Copyright (c) 2018 CercleFinance.com. All rights reserved.